Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Hussein Abdelwahab: FDA Approves Asundexian as the First Factor XIa Inhibitor for Stroke Prevention
Hussein Abdelwahab/LinkedIn
Nov 14, 2026, 13:41

Hussein Abdelwahab: FDA Approves Asundexian as the First Factor XIa Inhibitor for Stroke Prevention

Hussein Abdelwahab, Hospital Pharmacist at ‎Ibrahim Bin Hamad Obaid Allah Hospital, shared a post on LinkedIn about a recent article by Mukul Sharma et al, published in NEJM, adding:

“FDA Approved: Asundexian (Sunharbo) First in Class Factor XIa Inhibitor (November 9, 2026)

The U.S. FDA has approved Bayer’s asundexian (Sunharbo), the first oral selective Factor XIa inhibitor, for use with antiplatelet therapy to reduce the risk of recurrent stroke in adults following a recent non cardioembolic ischemic stroke (NIHSS low 15) or high risk TIA.

Why it matters: It targets the intrinsic pathway to reduce pathologic thrombosis while aiming to preserve natural hemostasis.

Key Evidence: OCEANIC STROKE (n equal 12,327)

Bullet 26 percent Relative Risk Reduction in ischemic stroke (6.2 percent asundexian plus antiplatelet vs. 8.4 percent placebo plus antiplatelet; HR 0.74; 95 plus CI 0.65 to 0.84; p low 0.0001).

Bullet Bleeding: Similar overall ISTH major bleeding rates between arms, though GI bleeding was more frequent with asundexian.

Clinical Practice Takeaways

Bullet Dose: 50 mg orally, once daily.

Bullet Caveat: NOT indicated for AFib or cardioembolic stroke prevention.

Bullet Caution: Not recommended in moderate to severe hepatic impairment (Child Pugh B or C).

A significant milestone in secondary stroke prevention. Careful patient selection and monitoring remain paramount.

References:

Title: Bayer’s SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack…

Authors: Mukul Sharma, Qiang Dong, Teruyuki Hirano, Scott E. Kasner, Jeffrey L. Saver, Jaime Masjuan, Andrew M. Demchuk, Charlotte Cordonnier, Daniel Bereczki, Georgios Tsivgoulis, Roland Veltkamp, Ivan Staikov, Hee-Joon Bae, Bruce C.V. Campbell, Andrea Zini, I-Hui Lee, Martin Kovar, Robert Mikulik, Robin Lemmens, José M. Ferro, Thompson Robinson, Hanne Christensen, Serefnur Ozturk, Ronen R. Leker, Peter Turcani, Agnieszka Slowik, Pablo Amaya, Fan Kee Hoo, Gian Marco De Marchis, Michael Knoflach, P.N. Sylaja, Jukka Putaala, Jonathan M. Coutinho, Bart van der Worp, Evija Miglane, Vaidas Matijošaitis, Arne G. Lindgren, Gisele Sampaio Silva, Else Charlotte Sandset, Saule T. Turuspekova, Pierre Amarenco, Kevin N. Sheth, Eric E. Smith, John W. Eikelboom, Raed A. Joundi, Karleen Schulze, M.Math., Lizhen Xu, Laura Heenan, Pablo Colorado, Lars Keller, Eva Muehlhofer, Christoph Neumann, Hardi Mundl, Ashkan Shoamanesh Hussein Abdelwahab: FDA Approves Asundexian as the First Factor XIa Inhibitor for Stroke Prevention

Stay updated on all scientific advances with Hemostasis Today.

Agnieszka Slowik Andrea Zini Andrew M. Demchuk Arne G. Lindgren Ashkan Shoamanesh Bart van der Worp Bruce C. V. Campbell Charlotte Cordonnier Christoph Neumann Daniel Bereczki Else Charlotte Sandset Eric E. Smith Eva Muehlhofer Evija Miglane Fan Kee Hoo Georgios Tsivgoulis Gian Marco De Marchis Gisele Sampaio Silva Hanne Christensen Hardi Mundl Health Hee-Joon Bae Hematology Hemostasis Hemostasis News Hemostasis Today Hussein Abdelwahab I-Hui Lee Ivan Staikov Jaime Masjuan Jeffrey L. Saver John W. Eikelboom Jonathan M. Coutinho José M. Ferro Jukka Putaala Karleen Schulze Kevin N Sheth Lars Keller Laura Heenan Lizhen Xu M.Math. Martin Kovar Medicine Michael Knoflach Mukul Sharma P.N. Sylaja Pablo Amaya Pablo Colorado Peter Turcani Pierre Amarenco Qiang Dong Raed A. Joundi Robert Mikulik Robin Lemmens Roland Veltkamp Ronen R. Leker Saule T. Turuspekova Scott E. Kasner Serefnur Ozturk Teruyuki Hirano Thompson Robinson Vaidas Matijošaitis
NewsFeed